CO*RE/ASAM Opioid Prescribing: Safe Practice, Changing Lives
- Registration Closed
Upcoming Courses:
April 29, 2016 - Washington, DC
This course incorporates all six units defined in the FDA blueprint for REMS education. The Opioid Prescribing: Safe Practice, Changing Lives course was developed to provide effective prescriber-focused education on the safe and effective prescribing of opioids. This course includes an ASAM created unit addressing ER/LA opioids and addiction.
CME Information and Disclosure Listing
The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.
The American Society of Addiction Medicine designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim credit commensurate with the extent of their participation in the activity.
This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 2 AMA PRA Category 1 Credits™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.
In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ASAM CME Committee
|
Name |
Nature of Relevant Financial Relationship |
||
|
Commercial Interest |
What was received? |
For what role? |
|
|
Adam J. Gordon, MD, MPH, FACP, DFASAM |
None |
||
|
Catherine Friedman, MD |
None |
||
| Noel Ilogu, MD, MRCP | None | ||
|
Herbert Malinoff, MD, FACP, DFASAM |
None |
||
|
Edwin A. Salsitz, MD, DFASAM |
None |
||
|
John Tanner, DO, DFASAM |
Reckitt Astra Zeneca Pfizer Alkermes |
Honorarium Honorarium Honorarium Honorarium |
Speaker Speaker Speaker Speaker |
Program Planning Committee & Faculty
Name | Nature of Relevant Financial Relationship | ||
Commercial Interest | What was received? | For what role? | |
Herbert Malinoff, MD, FACP, DFASAM | None | ||
Yngvild Olsen, MD, MPH | None | ||
Theodore Parran, MD |
None
| ||
Edwin Salsitz, MD, DFASAM | None | ||
R. Corey Waller, MD, MS, FACEP |
None
| ||
ASAM CME Committee Reviewers
Name | Nature of Relevant Financial Relationship | ||
Commercial Interest | What was received? | For what role? | |
Jacob Bobrowski, MD, FAAFP | None | ||
Anthony H. Dekker, DO, DFASAM | None | ||
Learners will be able to:
- Describe appropriate patient assessment for treatment with ER/LA opioid analgesics, evaluating risks and potential benefits of ER/LA therapy, as well as possible misuse.
- Apply proper methods to initiate therapy, modify dose, and discontinue use of ER/LA opioid analgesics, applying best practices including accurate dosing and conversion techniques, as well as appropriate discontinuation strategies.
- Demonstrate accurate knowledge about how to manage ongoing therapy with ER/LA opioid analgesics and properly use evidence-based tools while assessing for adverse effects.
- Employ methods to counsel patients and caregivers about the safe use of ER/LA opioid analgesics, including proper storage and disposal.
- Review/assess general and product-specific drug information concerning ER/LA opioid analgesics and identifying potential adverse effects of ER/LA opioids.
Acknowledgement
Presented by ASAM, a member of the Collaborative on REMS Education (CO*RE), 10 interdisciplinary organizations working together to improve pain management and prevent adverse outcomes.
RPC Commercial Support Disclosure Statement
This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see this link for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.
Key:
Complete
Next
Failed
Available
Locked